Takeda Pharmaceutical Company Limited
Price Action
Technical Summary
CONSOLIDATINGTakeda Pharmaceutical Company Limited is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 42), showing significant lag compared to the market leaders. Earnings growth of 76% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $15.66 | +1.12% | ABOVE |
| 50 SMA | $16.35 | -3.11% | BELOW |
| 100 SMA | $17.26 | -8.21% | BELOW |
| 150 SMA | $16.57 | -4.39% | BELOW |
| 200 SMA | $16.01 | -1.09% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TAK in an uptrend right now?
TAK has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is TAK overbought or oversold?
TAK's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.
Is TAK outperforming the market?
TAK has a Relative Strength (RS) Rating of 42 out of 99. TAK is currently lagging the broader market.
Where is TAK in its 52-week range?
TAK is trading at $15.84, which is 84% of its 52-week high ($18.89) and 48% above its 52-week low ($12.99).
How volatile is TAK?
TAK has a Beta of 0.35 and 52-week volatility of 20%. It's less volatile than the S&P 500 - generally more stable.